Communiqués Silo Pharma, Inc.

Actions

SILO

US82711P2011

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 05/07/2024			Varia. 5j.	Varia. 1 janv.
0,9626 ^USD	+0,80%		-3,74%	-33,15%

07/06	Silo Pharma sur le point d'atteindre la formulation optimale pour son implant de kétamine	MT
07/06	Silo Pharma annonce le succès de la production de son implant de kétamine SP-26 pour la fibromyalgie	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety	26/06	AQ
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia	07/06	AQ
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	05/06	AQ
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety	04/06	AQ
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	21/05	AQ
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine	14/05	AQ
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment	23/04	AQ
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic	10/04	AQ
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic	20/03	AQ
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18/03	AQ
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD	28/02	AQ
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14/02	AQ
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01/02	AQ
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study	24/01	AQ
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	04/01	AQ
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	28/12	AQ
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD	21/11	AQ
Silo Pharma : Material Agreement - Form 8-K	15/11	PU
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	08/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Silo Pharma, Inc.

Actions

SILO

US82711P2011

Communiqués

Filtres